Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 5 Next >
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and CD&R sign Opella share purchase agreement
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Execution of a share buyback agreement for up to €2 billion
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces buy back of shares from L’Oréal
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Opella reaches study milestone for Cialis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
From Sanofi - Aventis Groupe
Via GlobeNewswire
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q4 2024 Aide-mémoire
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi in discussions to sell a controlling stake in Opella
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.